SEC63

Across TCGA pan-cancer cohorts, SEC63 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SEC63 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SEC63 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEC63 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where SEC63 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.470	1.000	<.001	64	view →
LUAD	DFS	Tertile	II,III,IV	0.174	0.662	.004	11	view →
PDAC	DFS	Median	III,IV	0.315	0.708	.011	10	view →
OV	DFS	Median	All	0.632	0.902	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SEC63–CCRCC (OS)

Open the CCRCC breakdown →